0001209191-23-013438.txt : 20230227 0001209191-23-013438.hdr.sgml : 20230227 20230227200234 ACCESSION NUMBER: 0001209191-23-013438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230223 FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durgam Suresh K. CENTRAL INDEX KEY: 0001829958 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 23677710 MAIL ADDRESS: STREET 1: C/O INTER-CELLULAR THERAPIES, INC. STREET 2: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-23 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001829958 Durgam Suresh K. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 SVP, Chief Medical Officer Common Stock 2023-02-23 4 M 0 7906 A 31010 D Common Stock 2023-02-24 4 S 0 7906 47.14 D 23104 D Restricted Stock Units 2023-02-23 4 M 0 7906 0.00 D Common Stock 7906 7907 D Restricted stock units convert into common stock on a one-for-one basis. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.88 to $47.485, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline, Attorney-in-fact 2023-02-27